Clinical Trial

Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults

Study acronym: AGB101-CN
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This randomized, crossover, placebo controlled clinical study will assess the efficacy and safety of a slow release form of levetiracetam (AGB101) in the treatment of cognitively normal adults by measuring change in several imaging measures over the course of a two week treatment period.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-02; most recent amendment 2026-07-14.
Trial Details
NCT Number NCT06919926
Lead Sponsor Johns Hopkins University
Collaborators: AgeneBio, National Institute on Aging (NIA)
Conditions Hippocampal Overactivity, Dementia
Enrollment 60 participants
Start Date 2025-04-17
Primary Completion 2027-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-15